Medicines A–Z
C
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Co-amilofruse tablets |
Combination products should be avoided, unless compliance is an issue |
|
|
Co-beneldopa capsules | ||
|
|
Co-beneldopa dispersible tablets | ||
|
|
Co-beneldopa M/R capsules | ||
|
|
Co-careldopa M/R tablets | ||
|
|
Co-careldopa tablets | ||
|
|
Co-codamol 30/500 capsules |
Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
|
|
|
Co-codamol 30/500 effervescent tablets |
Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
|
|
|
Co-codamol 30/500 tablets |
Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
|
|
|
Co-Cyprindiol 2000/35 |
